Skip to search formSkip to main contentSkip to account menu

somatuline/suramin

Known as: Somatuline/SUR, Suramin/Somatuline 
National Institutes of Health

Related topics

Related topics

3 relations
SomatulineSuraminlanreotide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
18 The use of lanreotide in the treatment of congenital hyperinsulinism
Introduction The use of Lanreotide in the treatment of Congenital Hyperinsulinism (CHI) is now well-established (Shah et al, 2015… 
2016
2016
Grossesse acromégalique : quels risques et quelle prise en charge ?
2015
2015
Acrostart: Spanish retrospective study to determine the timeframe to achieve hormonal normalisation with initial Somatuline Autogel[reg] treatment in acromegaly patients in routine clinical practice
2014
2014
Traitement médical primaire des adénomes thyréotropes par les analogues de la somatostatine : à propos de 7 cas
2014
2014
Somatuline Autogel treatment in Acromegaly – 1 year data from SOPRANo study
2012
2012
Spotlight on Lanreotide Autogel® in Acromegaly
Lanreotide Autogel® (ATG) [Somatuline® Depot]1 is a novel, long-acting preparation of the somatostatin analog lanreotide acetate… 
2012
2012
The retrospective phase results of observational study Landro-Study assessing resource utilization in the population of polish acromegalic patients treated with Somatuline AUTOGEL
Review
2009
Review
2009
PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the University of Virginia Children ’ s Hospital Volume 15 Number 2 February 2009 Use of Ursodiol in Infants and…
rsodiol was approved by the Food and Drug Administration (FDA) in 1987 for the prevention and treatment of gallstones and for the… 
Review
2002
Review
2002
Somatuline Autogel: an extended release lanreotide formulation.
Somatuline Autogel provides effective control of growth hormone levels and is at least as effective as intramuscular Somatuline… 
2002
2002
Somatuline® autogel®*, une nouvelle forme galénique dans le traitement de l'acromégalie
Le lanreotide Autogel® est une nouvelle forme galenique du lanreotide administree mensuellement par voie sous-cutanee profonde… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)